Drugs - Xagena.net - Update in Medicine

Search results for "Pancreatic cancer"

Phase 1 trial evaluating MVT-5873 in combination with first-line chemotherapy in pancreatic cancer: promising early results

Interim results from the ongoing phase 1 trial evaluating MVT-5873 in combination with standard of care chemotherapy in patients newly diagnosed with pancreatic and other CA19-9 positive malignancies ... read article

Abraxane for metastatic pancreatic cancer, FDA approved

The Food and Drug Administration ( FDA ) has expanded the approved uses of Abraxane ( Paclitaxel protein-bound particles for injectable suspension, albumin-bound ) to treat patients with metastatic pa ... read article

Ruxolitinib in patients with refractory metastatic pancreatic cancer

Incyte has announced top-line results of the Phase II, randomized, double-blind, placebo-controlled RECAP trial of Ruxolitinib ( Jakafi ), its oral JAK1 and JAK2 inhibitor, in combination with Capecit ... read article

Type II diabetes: pancreatic cancer risk decreased by Metformin, increased by Insulin or insulin secretagogues

The antidiabetic medication Metformin is associated with a reduced risk of pancreatic cancer in diabetics, according to a new study in Gastroenterology. However, other commonly used therapies, such as ... read article

Gastrointestinal perforation, skin lesions or ocular disorders associated with Tarceva

Genentech and OSI Pharmaceuticals have informed Healthcare Professionals of new safety information regarding Tarceva ( Erlotinib ). Tarceva monotherapy is indicated for the treatment of patients wi ... read article

Bevacizumab associated with significantly increased risk of gastrointestinal perforation

Cancer patients treated with Bevacizumab ( Avastin ) in combination with chemotherapy are at significantly greater risk of potentially life-threatening gastrointestinal perforations, particularly pati ... read article

Focus

New indication for Eylea in EU: treatment of visual impairment due to macular edema secondary to central retinal vein occlusion

Bayer HealthCare has announced that Eylea ( Aflibercept solution for injection ) has been approved by the European Commission ( EC ) for the treatment of visual impairment due to macular edema seconda ... read article

Ibrutinib shows efficacy as treatment for chronic lymphocytic leukemia and mantle cell lymphoma

Two clinical studies published in the New England Journal of Medicine ( NEJM ) suggest that the novel agent Ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chro ... read article

Olmesartan Medoxomil can cause sprue-like enteropathy

FDA ( Food and Drug Administration ) has warned that the blood pressure drug Olmesartan Medoxomil ( marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics ) can cause intestinal problems know ... read article

Barrett's esophagus: Acetylsalicylic acid may fight cancer by slowing DNA damage

Aspirin ( Acetylsalicylic acid ) is known to lower risk for some cancers, and a new study led by a UC San Francisco researcher, Carlo Maley, points to a possible explanation, with the discovery that A ... read article

Metastatic or unresectable melanoma: FDA approves Tafinlar and Mekinist

The Food and Drug Administration ( FDA ) has approved two new drugs, Tafinlar ( Dabrafenib ) and Mekinist ( Trametinib ), for patients with advanced ( metastatic ) or unresectable melanoma, the most d ... read article

Giant cell tumor of the bone: FDA approves Xgeva

The Food and Drug Administration ( FDA ) has expanded the use of Xgeva ( Denosumab ) to treat adults and some adolescents with giant cell tumor of the bone ( GCTB ), a rare and usually non-cancerous t ... read article

Riociguat has demonstrated significant and sustained improvements in 6MWD and WHO functional class in patients with pulmonary arterial hypertension

Data from the interim analysis of the on-going PATENT-2 trial with Riociguat, the open-label long-term extension of the pivotal Phase III study PATENT-1, were presented at the American Thoracic Societ ... read article

Canagliflozin, a SGLT2 inhibitor, for the treatment of adults with type 2 diabetes

Janssen Pharmaceuticals has announced the FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) for the treatment of adults with type 2 diabetes. Invokana is the first in a new ... read article